Fake Drug claims : CDSCO Flags Spurious Drug Batches in June 2025 Surveillance
By PharmaGenDRx News Bureau – July 22, 2025
10:00 AM IST
As a part of its ongoing commitment to safeguard public health, the Central Drugs Standard Control Organization (CDSCO) has identified and listed multiple drug batches as purportedly spurious following its routine regulatory surveillance for the month of June 2025.
As mentioned in Drugs and Cosmetics Act 1940: Section 17-B, a drug is deemed to be spurious if falsified claims are found on labels, the product imitates another brand or is not manufactured by the company as claimed on its label or substituted by any other parts not desired or mentioned in label. These results are drawn by field sampling, testing and preliminary investigation conducted by Drug Inspectors who are in charge of particular states.
The drugs identified as under investigation for being spurious includes:
1. TAXIM-O 200 TABLETS (Cefixime Tablets IP)
2. 2.THROMBOPHOB (Heparin sodium and Benzyl Nicotinate)
3. Rosuvas F 10 Tablets (Rosuvastatin and Fenofibrate Tablets IP)
4. Rosuvas F 20 Tablets (Rosuvastatin and Fenofibrate Tablets IP)
In all four cases, the drugs failed assay tests. Manufacturers named on product labels officially denied production of identified batches leading to suspicions of counterfeiting.
With ongoing investigations, CDSCO urges consumers, pharmacists and healthcare professionals to remain alert and immediately report any suspected counterfeit products. The identification and removal of spurious drugs from the supply chain are critical in ensuring the safety and efficacy of medical treatment in India.
